6 employees
Arialys Therapeutics is a pre-clinical stage company that develops auto-antibody focusing on neuroscience.
2022
$58M
from 3 investors over 3 rounds
Arialys Therapeutics, Inc. raised $58M on September 12, 2023
Investors: Avalon BioVentures, MPM Capital and Catalys Pacific